ESMO welcomes media interested in obtaining information and reporting on cancer issues. Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card. Media representatives are required to observe and abide by the ESMO Media Policy which applies to all ESMO events.
To apply for media accreditation, please fill out the form available here:
- Newly discovered mechanism of action for air pollution induced non-small cell lung cancer paves the way to new potential approaches to lung cancer prevention and treatment (related content: LBA1)
- Targeting the right population with the right drug: the importance of designing rigorous randomised controlled Phase 3 trials in rare cancers to improve patients’ outcomes and quality of life (related content: LBA2 – DeFi)
- Results from the first randomised phase 3 trial with cell therapy in advanced melanoma (related content: LBA3 - M14TIL)
- Screening for multiple cancers simultaneously with a blood test to facilitate early detection of previously hard to find cancers (related content: 903O - PATHFINDER)
All abstracts are accessible as open-access resources through OncologyPRO.
Slides and webcasts
All registered journalists will have access to the post-Congress resources and on-demand content on the Meeting Resources section of OncologyPRO for six months following the Congress.
ESMO Daily Reporter
The Society’s official newspaper, ESMO Daily Reporter, is the source of Congress news, with the most relevant trial results, features and thought-provoking articles.